News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Incyte
NEWS
JOBS
IN THE PRESS
NEWS
Policy
Blood Clot Fears Delay Eli Lilly, Incyte’s Potential Rheumatoid Arthritis Blockbuster, Stocks Fall
July 25, 2017
·
3 min read
Deals
Why Incyte Is Still A Good Backup Plan For Gilead
July 14, 2017
·
1 min read
Business
Gilead’s Rumored M&A Target Incyte Doubled CEO’s Pay Package in 2016
April 18, 2017
·
1 min read
FDA
FDA Just Rejected Eli Lilly, Incyte’s Rheumatoid Arthritis Drug Baricitinib
April 14, 2017
·
2 min read
Deals
Why These 3 Drugmakers Could Buy Incyte
April 12, 2017
·
3 min read
Deals
What Happens if Gilead Went Bigger Than Incyte and Made a Play for This Pharma Giant
April 10, 2017
·
2 min read
BioCapital
After Soaring to $150, Can Incyte Stir Up More Upside?
March 16, 2017
·
1 min read
Deals
3 Reasons Why Gilead Will Buy Incyte—and 1 Reason Why It Won’t
March 15, 2017
·
1 min read
Deals
What a Gilead-Incyte Marriage Would Look Like
March 14, 2017
·
2 min read
AWARDS
JOBS
Currently, there are no jobs for this company on BioSpace
Browse all jobs
here
Oops!
There was an issue retrieving the jobs list. Please reload the page to view more jobs.
Title
Location
Company Name
Desc
View details
IN THE PRESS
Drug Development
Incyte Announces Results from SCRATCH-AD Trial Demonstrating Substantial and Rapid Itch Reduction in Patients with Mild-Moderate Atopic Dermatitis Treated with Opzelura® (ruxolitinib) Cream
May 1, 2023
·
15 min read
BioCapital
Incyte Announces European Commission Approval of Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents
April 20, 2023
·
8 min read
BioCapital
Incyte to Present at Upcoming Investor Conferences - April 18, 2023
April 18, 2023
·
1 min read
BioCapital
MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
April 16, 2023
·
14 min read
BioCapital
Incyte to Report First Quarter Financial Results - April 11, 2023
April 11, 2023
·
1 min read
Business
Biotheryx Announces Research Collaboration and License Agreement with Incyte for Discovery of Targeted Protein Degraders for Novel Oncology Targets
April 5, 2023
·
3 min read
Policy
Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)
March 27, 2023
·
7 min read
BioCapital
Incyte Provides Regulatory Update on Ruxolitinib Extended-Release Tablets
March 23, 2023
·
8 min read
FDA
Incyte Announces FDA Approval of Zynyz™ (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)
March 22, 2023
·
12 min read
Drug Development
Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
March 18, 2023
·
9 min read
